Low-risk myelodysplastic syndromes (LR-MDS) are complex blood disorders characterized by the abnormal proliferation and dysfunction of marrow cells, leading to increased risks of anemia, bleeding, and infection. Although the progression of LR-MDS is relatively slow, the treatment of this disease still faces significant challenges. Existing therapeutic options, such as erythropoiesis-stimulating agents (ESAs) and immunomodulators, may alleviate symptoms to some extent but often struggle to achieve long-term disease control and can be associated with significant side effects. Against this backdrop, Dr. Valeria Santini explored the potential of Imetelstat, a first-in-class oligonucleotide telomerase inhibitor, in treating patients with LR-MDS through the IMerge trial. The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) took place in Houston, USA, from September 4 to 7, 2024, bringing together top experts in the field of hematologic oncology worldwide to share the latest research findings and discuss new treatment strategies. Hematology Frontier specially invited Dr. Valeria Santini from the University of Florence, MDS Unit, Hematology, DMSC, AOUC, Florence, Italy, to delve into the research outcomes of this Phase III clinical trial, discussing the significant progress achieved by Imetelstat in improving the precision and effectiveness of LR-MDS patient treatment, and how this discovery may provide a new direction for future strategies in the MDS treatment field.
